Coronavirus Vaccine: AstraZeneca Vaccine Demonstrates 100% Protection "Against Hospitalization" Within 15 Days

The vaccine made by the British laboratory AstraZeneca and the University of Oxford against the coronavirus protects 100% two weeks after receiving the first dose. This has been assured by Bruno Holthof, executive director of Oxford University Hospitals since 2015 and Belgian by origin, in statements to the Belgian newspaper Het Nieuwsblad: “Two weeks after you are vaccinated with the first dose of our vaccine, you are practically 100% protected against hospitalization. After all, hospital admissions are the reason we are confined, “said Holthof. The executive director of Oxford hospitals gave this interview in the same week that the United Kingdom began to vaccinate with the prepared dose by the British laboratory AstraZeneca and the University of Oxford. The British Executive has ensured that there are more than 500,000 doses prepared to be distributed this week. One of the first Britons to be vaccinated is Brian Pinker, an 82-year-old man who received his dose at Oxford University Churchill Hospital. The Anglo-Saxon country is the first to use this vaccine to face the coronavirus pandemic. “By the end of January, we should have vaccinated six million British people,” said Bruno Holthof. “The first two of the nine priority groups include nursing home users and staff, health workers and more than three million people over 80 years of age. Our tests showed that the vaccine offers almost 100% protection against hospitalization after the first dose, and after all, hospital overload is the reason there are blockages.However, only two vaccinated subjects had to be hospitalized. The first with an infection that certainly developed before vaccination, the second perhaps as well. It means that now we can say: you are almost 100% protected against hospitalization two weeks after the first injection. A message that is important for confidence, “said the former director general of the ZNA hospitals in Antwerp, Belgium.” Lack of clarity “Holthof acknowledges the” lack of clarity “about the Oxford vaccine because during his elaboration process several data were given on its percentage of effectiveness. This vaccine was initially reported to be 62% effective, then 90% after a few and a half doses and around the Christmas holidays, AstraZeneca CEO Pascal Soriot said the “winning formula” I had 95%. “This was a cause for concern for those who doubt about vaccines,” said Bruno Holthof. “You have a different ending for each study that you have to record in advance. In our studies we measured asymptomatic infections, symptomatic infections, and infections with hospitalization. Figures previously published in the press referred only to symptomatic infections. They also come from intermediate analyzes. Now we communicate with a clear message: just once and you are protected against the effects that lead to infection. A second full dose of vaccine will last 12 weeks later, “explained the Belgian. It is still unknown if this vaccine will be effective against the new British super contagious strain of coronavirus that was discovered a few weeks ago. “But with mass vaccination, that should be known soon,” he indicated.“We have had our share of the anti-vaccine movement in recent months. We had protests at Oxford University, including an employee declared dead after vaccination. We had to ask on Twitter to be well informed of that case, “he has settled. The Oxford and AstraZeneca vaccine will also be produced in India, where 50 million doses will be produced per month. It is not yet known when this vaccine will arrive in a country of the European Union such as Belgium, which has requested 7.5 million doses of this vaccine. The European authorities have not yet given the green light to this vaccine, although they have received partial results of its tests. “I do not have enough knowledge of the European situation, but I believe that each country will need different vaccines,” admitted Bruno Holthof. Uğur Şahin, CEO of BioNTech and the scientist behind Pfizer’s coronavirus vaccine, also advocates that a campaign Vaccination of a single vaccine can “stall” the opening of society after the pandemic.